Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCD19 CAR T in Adult B-ALL with MRD Positivity
NCT05535855Phase 1Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Jan 2024
- Primary completion
- Jun 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cd19car-cd3zeta-4-1bb autologous t-lymphocyte cells in acute lymphoblastic leukemia (ALL), sponsored by University of Colorado Denver. Primary endpoints: Adverse Events at 30 days, Dose Limiting Toxicities at 42 days and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
cd19car-cd3zeta-4-1bb autologous t-lymphocyte cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05535855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05535855.